Literature DB >> 10102775

Effects of histamine H3 receptor ligands in experimental models of anxiety and depression.

C Pérez-García1, L Morales, M V Cano, I Sancho, L F Alguacil.   

Abstract

Histamine H3 receptor ligands have been proposed to be of potential therapeutic interest for the treatment of different central nervous system disorders; however, the psychopharmacological properties of these drugs have not been studied extensively. In this work, we investigated the possible involvement of histamine H3 receptor function in experimental models of anxiety (elevated plus-maze) and depression (forced swimming test). Male Sprague-Dawley rats were treated i.p. with the histamine H3 receptor agonist R-alpha-methylhistamine (10 mg/kg) or the histamine H3 receptor antagonist thioperamide (0.2, 2 and 10 mg/kg) and 30 min afterwards the time spent in the open arms of an elevated plus-maze was registered for 5 min. The immobility time of male OF1 mice in the forced swimming test was recorded for 6 min, 1 h after the i.p. administration of R-alpha-methylhistamine (10 and 20 mg/kg), thioperamide (0.2, 2, 10 and 20 mg/kg) or another histamine H3 receptor antagonist, clobenpropit (5 mg/kg). The locomotor activity of mice was checked in parallel by means of an activity meter. Both saline controls and active drug controls were used in all the paradigms. Neither thioperamide nor R-alpha-methylhistamine significantly changed animal behaviour in the elevated plus-maze. R-alpha-methylhistamine and the higher dose of thioperamide assayed (20 mg/kg) were also inactive in the forced swimming test. By contrast, thioperamide (0.2-10 mg/kg) dose-dependently decreased immobility, the effect being significant at 10 mg/kg (33% reduction of immobility); clobenpropit produced an effect qualitatively similar (24% reduction of immobility). None of these histamine H3 receptor antagonists affected locomotor activity. These preliminary results suggest that the histamine H3 receptor blockade could be devoid of anxiolytic potential but have antidepressant effects. Besides, the stimulation of these receptors does not seem to be followed by changes in the behavioural parameters studied.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102775     DOI: 10.1007/s002130050882

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum.

Authors:  Przemyslaw Nowak; Aleksandra Bortel; Joanna Dabrowska; Izabela Biedka; Grzegorz Slomian; Wojciech Roczniak; Richard M Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2008 May-Jun       Impact factor: 3.911

2.  Serotonergic neuron regulation informed by in vivo single-cell transcriptomics.

Authors:  Jennifer M Spaethling; David Piel; Hannah Dueck; Peter T Buckley; Jacqueline F Morris; Stephen A Fisher; Jaehee Lee; Jai-Yoon Sul; Junhyong Kim; Tamas Bartfai; Sheryl G Beck; James H Eberwine
Journal:  FASEB J       Date:  2013-11-05       Impact factor: 5.191

Review 3.  Mouse behavioural analysis in systems biology.

Authors:  Peter Van Meer; Jacob Raber
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

Review 4.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Anxiolytic-like profiles of histamine H3 receptor agonists in animal models of anxiety: a comparative study with antidepressants and benzodiazepine anxiolytic.

Authors:  Fumikazu Yokoyama; Miki Yamauchi; Masayo Oyama; Kunihiro Okuma; Kaname Onozawa; Takako Nagayama; Rie Shinei; Makoto Ishikawa; Yasuo Sato; Nobukazu Kakui
Journal:  Psychopharmacology (Berl)       Date:  2009-04-09       Impact factor: 4.530

Review 6.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

7.  Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases.

Authors:  C Y Jin; O Anichtchik; P Panula
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

8.  Effects of the H(3) antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration in rats.

Authors:  Mark E Bardgett; Megan Points; John Roflow; Meredith Blankenship; Molly S Griffith
Journal:  Psychopharmacology (Berl)       Date:  2009-05-23       Impact factor: 4.530

9.  Effects of methimepip and JNJ-5207852 in Wistar rats exposed to an open-field with and without object and in Balb/c mice exposed to a radial-arm maze.

Authors:  Rushdie M A Abuhamdah; Ruan van Rensburg; Natasha L Lethbridge; Abdel Ennaceur; Paul L Chazot
Journal:  Front Syst Neurosci       Date:  2012-07-16

10.  Hippocampal-Dependent Antidepressant Action of the H3 Receptor Antagonist Clobenpropit in a Rat Model of Depression.

Authors:  Teresa Femenía; Salvatore Magara; Caitlin M DuPont; Maria Lindskog
Journal:  Int J Neuropsychopharmacol       Date:  2015-03-11       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.